{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:01:29Z","timestamp":1791558089301,"version":"4.3.4"},"reference-count":81,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jaad.2020.05.089","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T17:31:38Z","timestamp":1596216698000},"page":"92-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Axial psoriatic arthritis: An update for dermatologists"],"prefix":"10.1016","volume":"84","author":[{"given":"Alice B.","family":"Gottlieb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.05.089_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.amepre.2014.02.012","article-title":"Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys","volume":"47","author":"Helmick","year":"2014","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jaad.2020.05.089_bib2","first-page":"280","article-title":"The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey","volume":"137","author":"Krueger","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib3","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib4","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib7","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2020.05.089_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2020.05.089_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: state of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.jaad.2020.05.089_bib10","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib11","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics","volume":"58","author":"Gottlieb","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/BOR.0000000000000152","article-title":"Recognizing and managing comorbidities in psoriatic arthritis","volume":"27","author":"Ogdie","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib13","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","article-title":"A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience","volume":"42","author":"Kane","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2020.05.089_bib14","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/art.22443","article-title":"A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time?","volume":"56","author":"Husted","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2020.05.089_bib15","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11926-007-0074-2","article-title":"Axial disease in psoriatic arthritis","volume":"9","author":"Gladman","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jaad.2020.05.089_bib17","first-page":"S31","article-title":"The involvement of the spine in psoriatic arthritis","volume":"33","author":"Baraliakos","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib18","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.3899\/jrheum.090412","article-title":"Axial psoriatic arthritis: update on a longterm prospective study","volume":"36","author":"Chandran","year":"2009","journal-title":"J Rheumatol"},{"issue":"Suppl 10","key":"10.1016\/j.jaad.2020.05.089_bib19","first-page":"2854","article-title":"Delay between the onset of psoriasis and arthritis in PsA patients from the PsART international cohort [abstract]","volume":"71","author":"Tascilar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib20","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1468-3083.2009.03463.x","article-title":"The risk of\u00a0psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics","volume":"24","author":"Christophers","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.05.089_bib21","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2012-201706","article-title":"High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires","volume":"72","author":"Haroon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib22","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/annrheumdis-2016-209853","article-title":"Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis","volume":"76","author":"Jadon","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib23","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3899\/jrheum.171094","article-title":"Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"45","author":"Mease","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib24","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.05.089_bib25","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/ced.12805","article-title":"Prevalence of psoriasis phenotypes among men and women in the USA","volume":"41","author":"Merola","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib26","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3899\/jrheum.101049","article-title":"Differential features between primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease","volume":"38","author":"Perez Alamino","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/art.21619","article-title":"Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria","volume":"54","author":"Rudwaleit","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2020.05.089_bib28","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/ard.2008.101501","article-title":"New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis International Society (ASAS)","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s100670200003","article-title":"Clinically asymptomatic axial disease in psoriatic spondyloarthropathy. A retrospective study","volume":"21","author":"Queiro","year":"2002","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib30","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jaad.2014.12.008","article-title":"Psoriatic arthritis: it's as easy as \u201cPSA\u201d","volume":"72","author":"Cohen","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 3","key":"10.1016\/j.jaad.2020.05.089_bib31","doi-asserted-by":"crossref","first-page":"iii22","DOI":"10.1136\/ard.2006.058453","article-title":"Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases?","volume":"65","author":"Gladman","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib32","first-page":"270","article-title":"Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis","volume":"35","author":"Haroon","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/rheumatology\/keg475","article-title":"Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis","volume":"43","author":"Williamson","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2020.05.089_bib34","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1136\/annrheumdis-2012-201884","article-title":"ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the Spondyloarthritis Caught Early (SPACE)-cohort and from the Assessment of Spondyloarthritis international Society (ASAS)-cohort","volume":"72","author":"van den Berg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/ard.59.1.67","article-title":"Characterisation of uveitis in patients with psoriatic arthritis","volume":"59","author":"Paiva","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib36","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3899\/jrheum.091059","article-title":"Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis","volume":"37","author":"Chandran","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib37","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3748\/wjg.v25.i18.2162","article-title":"Inflammatory bowel diseases and spondyloarthropathies: from pathogenesis to treatment","volume":"25","author":"Fragoulis","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaad.2020.05.089_bib38","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.3748\/wjg.v23.i33.6137","article-title":"Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases","volume":"23","author":"Halling","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaad.2020.05.089_bib39","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib40","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(74)91262-8","article-title":"HL-A 27 and arthropathies associated with ulcerative colitis and psoriasis","volume":"1","author":"Brewerton","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2020.05.089_bib41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41584-018-0006-8","article-title":"Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison","volume":"14","author":"Feld","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/rheumatology\/kev296","article-title":"HLA-B27 and psoriatic disease: a modern view of an old relationship","volume":"55","author":"Queiro","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2020.05.089_bib43","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1053\/sarh.2002.33470","article-title":"Psoriatic spondyloarthropathy: a comparative study between HLA-B27 positive and HLA-B27 negative disease","volume":"31","author":"Queiro","year":"2002","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2020.05.089_bib44","first-page":"469","article-title":"Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire","volume":"27","author":"Ibrahim","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib45","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/ard.2008.089441","article-title":"Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS)","volume":"68","author":"Gladman","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib46","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00403-009-0981-3","article-title":"Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire","volume":"301","author":"Dominguez","year":"2009","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2020.05.089_bib47","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/rheumatology\/kes187","article-title":"The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis","volume":"51","author":"Tinazzi","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2020.05.089_bib48","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/rheumatology\/key314","article-title":"Psoriatic arthritis screening: a systematic review and meta-analysis","volume":"58","author":"Iragorri","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2020.05.089_bib49","first-page":"597","article-title":"Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care","volume":"56","author":"Karreman","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2020.05.089_bib50","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3899\/jrheum.160717","article-title":"The juvenile psoriatic arthritis cohort in the CARRA registry: clinical characteristics, classification, and outcomes","volume":"44","author":"Zisman","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12969-018-0238-9","article-title":"Clinical features of children with enthesitis-related juvenile idiopathic arthritis\/juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre","volume":"16","author":"Goirand","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jaad.2020.05.089_bib52","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization international consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib53","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jbspin.2019.06.001","article-title":"The frequency of uveitis in patients with juvenile inflammatory rheumatic diseases","volume":"86","author":"Hayworth","year":"2019","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jaad.2020.05.089_bib54","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2217\/imt.15.85","article-title":"Interleukin-17 targeted therapies in axial spondyloarthritis","volume":"7","author":"Wendling","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaad.2020.05.089_bib55","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib56","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.33321","article-title":"Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats","volume":"64","author":"Glatigny","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2020.05.089_bib57","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib58","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib59","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2020.05.089_bib60","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","article-title":"Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis","volume":"74","author":"Callhoff","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib61","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib62","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2020.05.089_bib63","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2020.05.089_bib64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib65","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib66","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib67","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jaad.2020.05.089_bib68","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib69","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib70","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2018.04.012","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","volume":"79","author":"Gottlieb","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib71","doi-asserted-by":"crossref","first-page":"vi10","DOI":"10.1093\/rheumatology\/key217","article-title":"The current standard of care and the unmet needs for axial spondyloarthritis","volume":"57","author":"Noureldin","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2020.05.089_bib72","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/ard.2010.131797","article-title":"Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register","volume":"70","author":"Lie","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib73","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.05.089_bib74","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/rheumatology\/key375","article-title":"Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study","volume":"58","author":"Braun","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2020.05.089_bib75","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/annrheumdis-2019-eular.2932","article-title":"Secukinumab improves axial manifestations in patients with psoriatic arthritis and inadequate response to NSAIDs: primary analysis of the MAXIMISE trial","volume":"78","author":"Baraliakos","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib76","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib77","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2020.05.089_bib78","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"Deodhar","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib79","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2020.05.089_bib80","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2020.05.089_bib81","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220309592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220309592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:57:05Z","timestamp":1759273025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220309592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0190962220309592"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.05.089","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Axial psoriatic arthritis: An update for dermatologists","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.05.089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}